Patent details

LUC00093 Product Name: Rucaparib camsylate

Basic Information

Publication number:
LUC00093
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP117080945
Legal Status:
Inactive
Application number:
LUC00093
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/17/1250
Marketing Authorization Type:
Marketing Authorization Date:
29/05/2018
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
13/11/2018
First Marketing Authorization date:
29/05/2018
Grant date:
24/12/2019
Activation date:
Publication date:
15/11/2018
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
29/05/2033
SPC Extension Expiration:
29/05/2033
Rejection date:
Withdrawal date:

Owner

From:
13/11/2018
 
 

Name:
Pfizer Inc.
Address:
235 East 42nd Street, New York, NY 10017-5755, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
13/11/2018
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2018/13
Publication date:
13/12/2018
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2020/01
Publication date:
13/01/2020
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
28/02/2031
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
24/12/2019 Outgoing Correspondence 1
15/11/2018 Outgoing Correspondence 1
13/11/2018 Application Form 8
13/11/2018 General Document 44
13/11/2018 General Document 4
24/12/2019 Certificate 1
24/12/2019 Publication 1
15/11/2018 Publication 1
13/11/2018 General Document 3